Approval success rates of drug candidates based on target, action, modality, application, and their combinations. Issue 3 (8th April 2021)

• Record Type: Journal Article
• Authors: Yamaguchi, Shingo; Kaneko, Masayuki; Narukawa, Mamoru
• Is Part Of: Clinical and translational science. Volume 14:Issue 3(2021)
• Page Start: 1113
• Page End: 1122
• Publication Date: 2021-04-08
• Subjects: Medicine, Experimental -- Periodicals; Medical innovations -- Periodicals; 616.027
• DOI: 10.1111/cts.12980
• Languages: English
• ISSNs: 1752-8054

Abstract

Abstract: The current success rate of a drug candidate, from the beginning of the clinical trial to receiving marketing approval, is about 10%–20%, and it has not changed during the past few decades. Therefore, pharmaceutical companies are under pressure to select one compound, among many others, with a high probability of success. The differences in drug features affect their probabilities of approval success. In this study, we examined the approval success rates of drug candidates, developed in the United States, the European Union, or Japan, by focusing on four parameters ("drug target, " "drug action, " "drug modality, " and "drug application") and their combinations, and identified factors that conditioned the outcome of the drug development process. We obtained a total success rate of 12.8%, after evaluating 3999 compounds. Moreover, after analyzing the combinations of these parameters, the approval success rates of drugs that corresponded to the following categories—a stimulant in drug action or an enzyme in drug target and biologics (excluding monoclonal antibody) in drug modality—were high (34.1% and 31.3%, respectively). Univariate and multivariate logistic regression analyses revealed that stimulant in drug action, and "B" (blood and blood forming organs), "G" (genito‐urinary system and sex), and "J" (anti‐infectives for systemic use) in drug application were statistically associated with high approval success rates. We found several parameters and their combinations that affected drug approval success rates. Our results could assist pharmaceutical companies in evaluating the probability of success of their drug candidates and, thus, in efficiently conducting the clinical development process.